

1 **Title page**

2 **Article category:** Short communication

3 **Recommended manuscript title**

4 Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in
5 Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-
6 Blinded, Noninferiority Study

7
8 **Authors**

9 Masaharu Shinkai,¹ Takuhiro Sonoyama,² Akari Kamitani,² Risa Shibata,² Naomi
10 Seki,³ Shinya Omoto,³ Masahiro Shinoda,¹ Takashi Sato,¹ Naoki Ishii,⁴ Kenji
11 Igarashi,² Mari Ariyasu²

12
13 ¹Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
14 Shinagawa-ku, Tokyo 140-8522, Japan

15 ²Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F,
16 Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan

17 ³Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome,
18 Toyonaka, Osaka 561-0825, Japan

19 ⁴Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
20 Shinagawa-ku, Tokyo 140-8522, Japan

21
22 **Corresponding author:** Mari Ariyasu

23 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042,
24 Japan

25 Phone: +81-6-6209-6962

26 Fax: +81-6-6209-8047

27 Email: mari.tatsuno@shionogi.co.jp

28
29 Word count: 1983/2000

30 References: 19/20

31 Abstract word count: 150/150

32 Tables and multipanel figures: 4/4

33 Supplementary material: Appendix document, 5 tables, and 2 figures

34

35 **Abstract**

36 In this randomized, observer-blinded, phase 2/3 study, we assessed S-268019-b—a
37 recombinant spike protein vaccine. We analyzed the noninferiority of S-268019-b
38 (n=103), versus tozinameran (n=103), when given as a booster ≥ 6 months after the
39 2-dose tozinameran regimen in Japanese adults without prior COVID-19 infection.
40 Interim results showed that S-268019-b was noninferior to tozinameran in co-primary
41 endpoints: geometric mean titer (GMT) (126.42 versus 108.20; adjusted-GMT ratio
42 [95% CI], 1.17 [0.96-1.42]; noninferiority *P*-value, <0.0001) and seroresponse rate
43 (both 100%; noninferiority *P*-value, 0.0004) for neutralizing antibodies on day 29.
44 Both vaccines elicited anti-spike protein immunoglobulin G antibodies, and produced
45 T-cell response (n=30/group) and neutralized Delta and Omicron pseudovirus
46 variants (n=24/group) in subgroups. Most participants reported low-grade
47 reactogenicity on days 1 and 2, the most frequent being fatigue, fever, myalgia, and
48 injection-site pain. No serious adverse events were reported. S-268019-b safety and
49 robust immunogenicity as a booster, supporting its use as COVID-19 booster
50 vaccine.

51

52 **Keywords:** booster, clinical trial, neutralization test, SARS-CoV-2, recombinant
53 spike protein, immunization

54

55 **JRCT ID:** jRCT2031210470

56 **Highlights**

- 57 • Third COVID-19 vaccine dose (booster) enhances immune response
- 58 • Interim phase 2/3 data for booster ≥ 6 months after the 2nd dose in Japan are
59 shown
- 60 • S-268019-b and tozinameran were safe and equal in inducing neutralizing
61 antibodies
- 62 • Both boosters neutralized Delta and Omicron pseudovirus and induced T-cell
63 response
- 64 • Results support use of S-268019-b as a booster in vaccinated adults

65 **Introduction**

66 Cases of coronavirus disease 2019 (COVID-19) caused by severe acute
67 respiratory syndrome coronavirus 2 (SARS-CoV-2) are increasing periodically
68 because of several reasons. A third vaccine dose (booster) is recommended
69 because of concerns regarding waning humoral immunity over 6 months after the
70 second dose [1] and consequent reduced effectiveness against SARS-CoV-2
71 infection [2], as well as threats from new mutant strains that may escape the
72 vaccine-mediated immunity. Booster immunization can substantially improve the
73 humoral immune response against the emerging variants, including Omicron [3], [4].

74 Shionogi & Co., Ltd., has developed a novel vaccine candidate—S-268019-
75 b—comprising a modified recombinant spike protein of SARS-CoV-2 (S-910823,
76 antigen) produced using the baculovirus expression system in insect cells and a
77 squalene-based adjuvant (A-910823). In a double-blinded, phase 1/2 trial, S-268019-
78 b showed tolerability and a robust immunogenic response 4 weeks after the second
79 dose [5, Unpublished results]. Here, we present the interim results of a phase 2/3,
80 randomized trial, wherein the immunogenicity and safety of a single booster dose of
81 S-268019-b or tozinameran were assessed in Japan.

82

83 **Methods**

84 *Study design and participants*

85 This phase 2/3, single-center, randomized, observer-blinded, active-
86 controlled, noninferiority trial comprised three periods: screening (day -28 to -1),
87 evaluation (day 1 to 29), and follow-up (day 30 to 365) (**Figure 1**).

88 Participants were healthy immunocompetent Japanese adults (aged ≥ 20 years)
89 who had received two doses of tozinameran (BNT162b2; *Pfizer/BioNTech* mRNA
90 vaccine), with the second dose received ≥ 6 months ago. Individuals with laboratory-
91 confirmed SARS-CoV-2 infection at screening or known history of SARS-CoV-2
92 infection were excluded (See **Supplementary Methods** for details).

93 Eligible participants were randomized 1:1, stratified by age (<40 and ≥ 40
94 years) and sex, to receive an intramuscular injection of either 0.5 mL of S-268019-b
95 (10 μg antigen prepared with 50% v/v oil-in-water adjuvant emulsion) or 0.3 mL of
96 tozinameran (30 μg in saline) on day 1.

97 The study (jRCT2031210470) was conducted in compliance with the protocol,
98 the Declaration of Helsinki and Council for International Organizations of Medical

99 Sciences International Ethical Guidelines, the International Council for
100 Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good
101 Clinical Practice Guidelines, other applicable laws and regulations, and was
102 approved by Institutional Review Board of Tokyo Shinagawa Hospital Medical
103 Corporation Association Tokyokyojuno-kai. All participants gave their written
104 informed consent.

105

106 *Outcomes*

107 The primary objective of the study was to assess the noninferiority of
108 S-268019-b versus tozinameran as a booster dose in inducing SARS-CoV-2
109 neutralizing antibodies on day 29. The co-primary endpoints included day 29
110 geometric mean titer (GMT) and seroresponse rate (SRR) for SARS-CoV-2
111 neutralizing antibodies. SRR was defined as the proportion of participants with a
112 post-vaccination antibody titer ≥ 4 -fold higher than the baseline.

113 Secondary endpoints comprised other immunogenicity parameters and safety.
114 These included GMT, geometric mean fold rise (GMFR), and SRR for neutralizing
115 antibodies and anti-spike protein immunoglobulin G (IgG) antibodies on days 15 and
116 29. Exploratory analyses in a smaller sample included geometric means of 50%
117 neutralization titer (NT_{50}) against SARS-CoV-2 pseudovirus strains (wildtype
118 [D614G], Delta, and Omicron) on day 29 and T-cell response on day 15. Safety
119 endpoints included incidence of adverse events (AEs), serious AEs, AEs of special
120 interest, treatment-related AEs (TRAEs), medically attended TRAEs, solicited
121 TRAEs, and changes in laboratory test values. Immunogenicity variables with titer
122 values below the lower limit of quantification (LLOQ) were replaced with $0.5 \times$ LLOQ.

123

124 *Statistical analyses*

125 The study used a noninferiority design. Noninferiority of S-268019-b to
126 tozinameran is confirmed when the lower limit of 95% CI is >0.67 for GMT ratio
127 (S-268019-b/tozinameran) derived from the analysis of covariate model with age and
128 sex as covariates, and more than -10% for SRR difference (S-268019-b minus
129 tozinameran) by the Farrington-Manning method for neutralizing antibodies on day
130 29 [6]. The immunogenicity subset included participants who received ≥ 1 dose of the
131 study intervention, had ≥ 1 post-vaccination immunogenicity data, and were negative
132 for anti-SARS-CoV-2 N-protein antibody at screening. The safety analysis subset

133 included participants who received ≥ 1 dose of the study intervention. All analyses
134 were conducted based on the actual intervention administered.

135 Data were summarized using measures of central tendency, dispersion, and
136 frequency distribution. Unless otherwise noted, all statistical tests were performed at
137 the two-sided $\alpha=0.05$. Missing values were not imputed. All analyses were
138 performed using SAS[®] v9.4 (SAS Institute, NC, USA). (See **Supplementary**
139 **Appendix** for detailed methods and statistical analyses).

140

141 **Results**

142 *Trial Participants*

143 All 206 participants screened were enrolled in the study (S-268019-b, n=103;
144 tozinameran, n=103) during December 3–22, 2021 (**Supplementary Figure 1**).
145 Baseline demographics and participant characteristics were balanced across
146 S-268019-b and tozinameran groups: median age (range) was 30.0 (21-59) and 31.5
147 (21-60) years; male population, 70% and 72%, respectively (**Supplementary Table**
148 **1**).

149

150 *Immunogenicity*

151 Per day 29 analysis, both co-primary endpoints were met: as a booster,
152 S-268019-b was noninferior to tozinameran in SARS-CoV-2 neutralization. GMTs
153 (95% CIs) for neutralizing antibodies at baseline were 5.53 (4.87-6.28) for S-
154 268019-b group and 6.70 (5.76-7.78) for tozinameran, which increased to 126.42
155 (109.76-145.62) and 108.20 (94.57-123.80), respectively, by day 29 (adjusted-
156 GMTR 1.17; 95% CI 0.96-1.42; one-sided *P*-value for noninferiority, <0.0001). The
157 SRR was 100% for both groups (SRR difference 0.0; 95% CI –5.8 to 5.8; one-sided
158 *P*-value for noninferiority, 0.0004) (**Figure 2A and Table 1**). The GMTs (95% CIs) for
159 anti-spike protein IgG antibodies at baseline were 1475.9 (1280.1-1701.6) for S-
160 268019-b and 1795.9 (1536.9-2098.6) for tozinameran; these were elevated to
161 48844.0 (41855.3-56999.7) and 55214.8 (49013.5-62200.7), respectively, on day 29
162 (**Figure 2B**), with both groups showing 100% SRR (**Supplementary Table 2**). The
163 GMFR and GMT results were consistent (**Supplementary Table 2 and Figure 2**).

164 Furthermore, the geometric mean NT₅₀ against SARS-CoV-2 pseudovirus
165 variants on day 29 were assessed in a smaller sample of the immunogenicity subset

166 (n=24/group). The sampling ensured no significant differences in age and
167 neutralizing antibody titer against live wildtype virus on day 29 compared with the
168 entire cohort (**Supplementary Table 3**). Serum samples from both vaccine groups
169 neutralized Delta and Omicron pseudovirus variants with similar potency, as
170 indicated by NT₅₀ values relative to tozinameran (**Figure 2C**). T-cell responses were
171 assessed for a subgroup (n=30/group) sampled from participants who gave consent
172 for cellular immunity assessments. Both vaccines induced antigen-specific
173 polyfunctional CD4⁺ T-cell responses, as reflected in the interferon-gamma and
174 interleukin-2 expression on day 15 (**Supplementary Figure 2**). A strong bias toward
175 the T-helper type 1 phenotype was noted.

176

177 *Safety*

178 Both, S-268019-b and tozinameran, displayed an acceptable safety profile as
179 a booster. There were no treatment-emergent serious AEs, deaths, grade 4-5
180 solicited TRAEs, or AEs of special interest reported until data cutoff date (February
181 4, 2022) (**Supplementary Table 4**). Overall, 96.1% (99/103) participants reported
182 375 TRAEs in the S-268019-b group, and 98.1% (101/103) participants reported 464
183 TRAEs in the tozinameran group. Furthermore, solicited systemic TRAEs were
184 reported by 69.9% (72/103) and 78.6% (81/103) participants and solicited local
185 TRAEs by 68.0% (70/103) and 72.8% (75/103) participants in the S-268019-b and
186 tozinameran groups, respectively. The most frequently reported solicited TRAEs
187 within 7 days in both booster groups were injection-site pain, fatigue, fever, myalgia,
188 and headache (**Table 2**). Most of the solicited TRAEs were grade 1-2 and were
189 reported on day 1-2 of the booster dose injection (**Supplementary Table 5**). One
190 participant in the S-268019-b group and four participants in the tozinameran group
191 experienced grade 3 solicited TRAEs.

192

193 **Discussion**

194 This study showed that S-268019-b as a booster (third) dose was noninferior
195 to tozinameran in inducing SARS-CoV-2 neutralizing antibodies. Both vaccines
196 induced neutralizing antibodies against pseudovirus variants, and also elicited anti-
197 spike protein IgG antibodies and T-cell responses within a month after the booster
198 dose.

199 In other booster-dose studies, a third dose of either homologous or
200 heterologous vaccines administered 3-9 months after the initial vaccination elicited
201 robust immunogenicity against SARS-CoV-2 variants [7], [8], [9], [10], [11], [12]. In
202 the COV-BOOST trial, immunogenicity of various types of vaccines given as the third
203 dose was assessed in participants with primary vaccination with either tozinameran
204 or AZD-1222 [12]. While the booster dose of all types of vaccines (mRNA, protein
205 subunit, adenovirus vector, and inactivated virus) amplified immune responses,
206 mRNA vaccines (tozinameran and mRNA-1273) induced more potent
207 immunogenicity than other types of vaccines [12]. Considering that S-268019-b
208 booster is as immunogenic as the tozinameran booster, S-268019-b may elicit more
209 potent humoral immunogenicity than other types of vaccines in the COV-BOOST
210 study, although a direct comparison is not possible.

211 Although no correlates of protection have been established in COVID-19, the
212 neutralizing antibody titer against SARS-CoV-2 after primary vaccination is highly
213 correlated with clinical efficacy against symptomatic COVID-19 [13]. Humoral
214 immunity in COVID-19 is known to wane over time, especially after 6 months [1], and
215 so does protection against symptomatic COVID-19 [2]. In this study, lower baseline
216 titers for neutralizing antibodies ≥ 6 months after the 2-dose tozinameran vaccination
217 were observed, consistent with previous reports. Meanwhile, studies have reported
218 that a booster dose of tozinameran after 2 doses of tozinameran enhances humoral
219 immunity [7], [12]. Moreover, a report from Israel stated greater efficacy against
220 COVID-19-related hospitalization and death after three versus two tozinameran
221 doses [14]. Since our results show noninferiority of S-268019-b to tozinameran in
222 inducing neutralizing antibodies, it is speculated that S-28019-b may also show
223 clinical efficacy similar to the booster tozinameran, although further investigations to
224 support this theory are warranted.

225 A previous study showed that the NT_{50} against the live Omicron virus after
226 two doses of tozinameran was below the detection limit and 61-fold lower compared
227 with the wildtype NT_{50} [15]. However, the third (booster) dose of tozinameran elicited
228 neutralizing antibody titer against Omicron, with NT_{50} only 6-fold lower than that with
229 the wildtype [15]. Moreover, the tozinameran booster dose protected against
230 symptomatic COVID-19 due to Omicron [16]. The current findings showing that
231 S-268019-b and tozinameran are similar with respect to neutralizing antibody levels

232 against Omicron suggest that S-28019-b might also show similar clinical efficacy
233 against symptomatic COVID-19 due to Omicron.

234 The T-cell response in COVID-19 is crucial for sustained protection from
235 severe disease progression [17], [18]. Additionally, the T-cell response elicited by
236 COVID-19 infection or prior vaccination is considered cross-reactive against other
237 variants, including Omicron [19]. In the current study, we only examined the T-cell
238 response to the original wildtype strain, in which S-268019-b showed a response
239 similar to tozinameran. However, due to the cross-reactive nature of the T-cell
240 response, it is speculated that the T-cell response elicited by S-268019-b may
241 possibly be effective in preventing severe diseases caused by Omicron and other
242 future variants.

243 In this study, both vaccines led to mainly low-grade reactogenicity, with fever,
244 fatigue, myalgia, and injection-site pain being commonly reported, usually within 2
245 days of the booster dose. Compared with tozinameran, S-268019-b led to a lower
246 incidence of solicited TRAEs. Similarly, across all 7 booster vaccines in the
247 COV-BOOST trial, the most frequently solicited AEs reported within 7 days were low-
248 grade fatigue, headache, and local pain [12]. Despite the differences in population
249 and methodologies across different studies, reactogenicity patterns seem largely
250 consistent across studies after the booster dose of either an mRNA [7], [8],
251 adenovirus vector [9], or protein subunit vaccine [10], [11], [12].

252 This is the first clinical trial report of a recombinant spike protein vaccine
253 showing its noninferiority to an mRNA vaccine as a booster dose in Japanese
254 participants. Some limitations of this study must however be acknowledged. The
255 study (1) was designed for an immunocompetent adult Japanese cohort with no
256 known history of SARS-CoV-2 infection and prior vaccination with only tozinameran,
257 and (2) has a short follow-up duration for interim analysis and relatively small sample
258 size. Also, this study was not powered to demonstrate clinical efficacy. Despite these
259 limitations, a booster dose of the recombinant spike protein vaccine, S-268019-b,
260 elicited robust immunogenicity against SARS-CoV-2, with mostly low-grade
261 reactogenicity.

262

263 **Conclusion**

264 The booster dose of S-268019-b vaccine was noninferior to tozinameran
265 booster as per the findings of GMT and SRR for SARS-CoV-2 neutralizing

266 antibodies, and was well-tolerated in fully vaccinated adult Japanese participants.
267 S-268019-b booster was comparable with tozinameran booster in neutralizing the
268 pseudovirus variants, Delta and Omicron. Thus, S-268019-b might be a future option
269 for COVID-19 booster vaccine in adults.

270

271 **Funding:** This work was supported by Shionogi & Co., Ltd., and Ministry of Health,
272 Labour and Welfare (MHLW) under its supplementary budget for emergency
273 maintenance associated with the vaccine production system. Preparation of clinical
274 trial materials of S-268019-b was supported by Japan Agency for Medical Research
275 and Development (AMED) under Grant Number JP21nf010626.

276

277 **Acknowledgments:** The authors thank Ms. Kiyomi Kabasawa, Ms Wakana Abe, Ms
278 Harue Otsuka, Ms. Emi Kawabe, Ms. Narumi Iida, and Ms Etsuko Tanaka for
279 supporting clinical trials as clinical research coordinator, and Dr. Kenichi Kamachi
280 and all the staff of Tokyo Shinagawa Hospital for supporting the clinical trials, and
281 Ms. Haruna Hayashi and Mr. Satoshi Kojima (Shionogi & Co., Ltd.) for supporting
282 manuscript development. The authors also thank Dr. Minal Jaggar, PhD, Dr. Vidula
283 Bhole, MD, MHSc, and Mr. Ivan D'Souza, MS, of MedPro Clinical Research for
284 providing medical writing support for this manuscript, which was funded by Shionogi
285 & Co., Ltd.

286

287 **Disclosures/potential conflicts of interests**

288 M. Shinkai, M. Shinoda, T. Sato, and N. Ishii have no conflicts of interest to declare.
289 TS, AK, RS, NS, SO, KI, and MA are employees of Shionogi & Co., Ltd.

290 References

- 291 [1] Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning
292 immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N*
293 *Engl J Med* 2021;385:e84. <https://doi.org/10.1056/nejmoa2114583>
- 294 [2] Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et
295 al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a
296 large integrated health system in the USA: a retrospective cohort study.
297 *Lancet* (London, England) 2021;398:1407–16. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02183-8)
298 [6736\(21\)02183-8](https://doi.org/10.1016/S0140-6736(21)02183-8)
- 299 [3] Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan
300 ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing
301 immunity against SARS-CoV-2 Omicron variant. *Cell* 2022;185:457–66.
302 <https://doi.org/10.1016/J.CELL.2021.12.033>
- 303 [4] Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et
304 al. mRNA booster immunization elicits potent neutralizing serum activity
305 against the SARS-CoV-2 Omicron variant. *Nat Med* 2022:1–4.
306 <https://doi.org/10.1038/s41591-021-01676-0>
- 307 [5] Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, et al.
308 Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: a report
309 of interim findings. [Vaccine: Submitted].
- 310 [6] Office of Vaccines and Blood Products, Pharmaceuticals and Medical Device
311 Agency, Japan. Principles for the evaluation of vaccines against the novel
312 coronavirus SARS-CoV-2 (Appendix 3).
313 <https://www.pmda.go.jp/files/000243339.pdf>; 2021 [accessed 25 February
314 2022].
- 315 [7] Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al.
316 SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. *N Engl J Med*
317 2021;385:1627–9. <https://doi.org/10.1056/NEJMc2113468>
- 318 [8] Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity
319 of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim
320 analysis. *Nat Med* 2021;27:2025–31. [https://doi.org/10.1038/s41591-021-](https://doi.org/10.1038/s41591-021-01527-y)
321 [01527-y](https://doi.org/10.1038/s41591-021-01527-y)
- 322 [9] Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al.
323 Reactogenicity and immunogenicity after a late second dose or a third dose of
324 ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials
325 (COV001 and COV002). *Lancet* 2021;398:981–90.
326 [https://doi.org/10.1016/S0140-6736\(21\)01699-8](https://doi.org/10.1016/S0140-6736(21)01699-8)
- 327 [10] Mallory R, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al.
328 Immunogenicity and safety following a homologous booster dose of a SARS-
329 CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2
330 randomized placebo-controlled trial. *MedRxiv* 2021:2021.12.23.21267374.
331 <https://doi.org/10.1101/2021.12.23.21267374>
- 332 [11] Cao Y, Hao X, Wang X, Wu Q, Song R, Zhao D, et al. Humoral
333 immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two

- 334 doses of inactivated vaccine. *Cell Res* 2021;32:107–9.
335 <https://doi.org/10.1038/s41422-021-00596-5>
- 336 [12] Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al.
337 Safety and immunogenicity of seven COVID-19 vaccines as a third dose
338 (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
339 (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
340 *Lancet* 2021;398:2258–76. [https://doi.org/https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02717-3)
341 [6736\(21\)02717-3](https://doi.org/10.1016/S0140-6736(21)02717-3)
- 342 [13] Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
343 Neutralising antibody titres as predictors of protection against SARS-CoV-2
344 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe*
345 2022;3:e52–61. [https://doi.org/10.1016/S2666-5247\(21\)00267-6](https://doi.org/10.1016/S2666-5247(21)00267-6)
- 346 [14] Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al.
347 Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for
348 preventing severe outcomes in Israel: an observational study. *Lancet*
349 (London, England) 2021;398:2093–100. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02249-2)
350 [6736\(21\)02249-2](https://doi.org/10.1016/S0140-6736(21)02249-2)
- 351 [15] Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al.
352 Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited
353 human sera. *Science* 2022;375:678–80.
354 <https://doi.org/10.1126/science.abn7591>
- 355 [16] Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al.
356 Association between 3 doses of mRNA COVID-19 vaccine and symptomatic
357 infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA*.
358 2022;327(7):639–51. [https://doi:10.1001/jama.2022.0470](https://doi.org/10.1001/jama.2022.0470)
- 359 [17] Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell
360 and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term
361 immune responses in COVID-19 convalescent individuals. *Sci Transl Med*
362 2021;13:7517. <https://doi.org/10.1126/scitranslmed.abf7517>
- 363 [18] Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol*
364 2022;23:186–93. <https://doi.org/10.1038/s41590-021-01122-w>
- 365 [19] Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, et al. Ancestral
366 SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med*
367 2022:1–5. <https://doi.org/10.1038/s41591-022-01700-x>

368 **Figure legends**

369 **Figure 1:** Study design, vaccine regimen, and key assessments

370

371 NT₅₀, 50% neutralization titer.

372

373 **Figure 2:** GMTs in the tozinameran and S-268019-b groups for (A) neutralizing
374 antibodies against live wildtype virus by cytopathic effect, (B) anti-spike protein IgG,
375 and (C) relative NT₅₀ against pseudotyped virus variants

376

377 GMT, geometric mean titer; IgG, immunoglobulin G; LLOQ, lower limit of
378 quantification; NT₅₀, 50% neutralization titer.

379 Data are presented as GMTs and 95% CIs. In Figure 2C, white and grey circles
380 represent individual relative NT₅₀ values for the tozinameran (n=24) and S-268019-b
381 (n=24) groups, respectively, relative to group GMT for tozinameran, on day 29.

382 Titer values reported as below the LLOQ were replaced with 0.5 × LLOQ. The LLOQ
383 was 5 for neutralizing antibodies and 100 for anti-spike protein IgG. The 95% CI
384 were constructed using Student's *t* distribution for log-transformed titers.

385

386 **Supplementary Figure 1:** Participant flow

387

388 **Supplementary Figure 2:** Immunologic assays from PBMCs for percent of CD4⁺ T
389 cells positive for IFN- γ , IL-2, IL-4, and IL-5 at baseline and on day 15 in the study
390 groups

391

392 IFN, interferon; IL, interleukin; PBMCs, peripheral blood mononuclear cells.

393 Data are presented as mean and 95% CI. Dark circles represent baseline and light
394 squares represent day 15 values of immune marker expression for individual
395 participants in the study groups (n=30/group). The 95% CI were constructed using
396 the Clopper-Pearson method for proportion data.

397 **Table 1:** Co-primary endpoints (GMT and SRR) with GMTR and SRR difference in
 398 SARS-CoV-2 neutralizing antibody response on day 29, and GMT and SRR at
 399 baseline and on day 15

Outcome (95% CI)	Tozinameran (n=101)			S-268019-b (n=103)		
	Baseline ^a	Day 15	Day 29	Baseline	Day 15	Day 29
GMT ^b	6.70 (5.76, 7.78)	138.53 (121.61, 157.80)	108.20 (94.57, 123.80)	5.53 (4.87, 6.28)	128.14 (112.79, 145.57)	126.42 (109.76, 145.62)
GMTR ^c	-	-	-	-	-	1.17 (0.96, 1.42)
SRR ^d	-	99.0 (94.6, 100.0)	100.0 (96.4, 100.0)	-	100.0 (96.5, 100.0)	100.0 (96.5, 100.0)
SRR difference ^d	-	-	-	-	-	0.0 (-5.8, 5.8)

400 GMT, geometric mean titer; GMTR, geometric mean titer ratio; SARS-CoV-2, severe
 401 acute respiratory syndrome coronavirus 2; SRR, seroresponse rate.

402 Criteria for noninferiority confirmed when lower limit of 95% CI >0.67 for GMTR
 403 (S-268019-b/tozinameran) and > -10% for SRR difference (S-268019-b -
 404 tozinameran).

405 ^aAt baseline, tozinameran group had 102 participants. ^bThe GMTs with
 406 corresponding 95% CIs were estimated by back transformation from the arithmetic
 407 mean and the 95% CIs based on the Student's *t* distribution of log-transformed titers
 408 to the original scale. ^cThe GMTR and its 95% CI were obtained using analysis of
 409 covariance model fitted on the log-transformed titers; the model included intervention
 410 group as the fixed effect as well as age (continuous) and sex as covariates. ^dThe
 411 95% CI were constructed using the Clopper-Pearson method for SRR and the
 412 Farrington-Manning method for SRR difference.

413 **Table 2:** Incidence of solicited local and systemic treatment-related adverse events (experienced within 7 days after the booster) by
 414 severity in the study groups

	Tozinameran (n=103)				S-268019-b (n=103)			
	Any grade	Grade 1	Grade 2	Grade 3	Any grade	Grade 1	Grade 2	Grade 3
Any systemic solicited TRAEs	81 (78.6)	46 (44.7)	31 (30.1)	4 (3.9)	72 (69.9)	56 (54.4)	15 (14.6)	1 (1.0)
Fatigue	55 (53.4)	32 (31.1)	22 (21.4)	1 (1.0)	45 (43.7)	36 (35.0)	9 (8.7)	-
Fever	61 (59.2)	52 (50.5)	7 (6.8)	2 (1.9)	40 (38.8)	37 (35.9)	2 (1.9)	1 (1.0)
Myalgia	49 (47.6)	42 (40.8)	7 (6.8)	-	42 (40.8)	41 (39.8)	1 (1.0)	-
Headache	43 (41.7)	31 (30.1)	12 (11.7)	-	26 (25.2)	19 (18.4)	7 (6.8)	-
Arthralgia	12 (11.7)	7 (6.8)	5 (4.9)	-	8 (7.8)	6 (5.8)	2 (1.9)	-
Nausea/vomiting	5 (4.9)	5 (4.9)	-	-	5 (4.9)	4 (3.9)	1 (1.0)	-
Diarrhea	6 (5.8)	4 (3.9)	1 (1.0)	1 (1.0)	4 (3.9)	3 (2.9)	1 (1.0)	-
Chills	7 (6.8)	3 (2.9)	4 (3.9)	-	4 (3.9)	2 (1.9)	2 (1.9)	-
Any local solicited TRAEs (at the injection site)	75 (72.8)	70 (68.0)	5 (4.9)	-	70 (68.0)	68 (66.0)	2 (1.9)	-
Pain	75 (72.8)	70 (68.0)	5 (4.9)	-	68 (66.0)	68 (66.0)	-	-
Erythema/redness	9 (8.7)	9 (8.7)	-	-	7 (6.8)	6 (5.8)	1 (1.0)	-
Swelling	1 (1.0)	1 (1.0)	-	-	1 (1.0)	-	1 (1.0)	-

415 TRAEs, treatment-related adverse events.

416 Data are presented as number (%) of the participants. No participants reported grade 4 or 5 solicited TRAEs.

Primary endpoints: geometric mean titer and seroresponse rate of neutralizing antibodies on day 29

Secondary endpoints: geometric mean titer, geometric mean fold rise and seroresponse rate of neutralizing antibodies and anti-spike protein IgG antibodies, incidence of adverse events (AEs), treatment-related AEs, serious AEs, solicited AEs, and changes in vital signs, laboratory test values and electrocardiograms

Exploratory endpoints: NT₅₀ against pseudovirus variants and T-cell cytokine assay

Screening

Evaluation

Follow-up

Healthy adults vaccinated with 2 doses of tozinameran ≥6 months ago (age 20-60 years)

Randomization (1:1)

Location: Japan

Candidate vaccine: 10 µg of S-268019-b in A-910823 (50% v/v)


Active-control: 30 µg of tozinameran in saline





Intramuscular injection of booster (3rd) dose

Study site visit on days 69, 183, and 365 for investigations/examinations

Informed consent and eligibility

Study site visit on days 2, 15, and 29 for investigations/examinations



A**B****C**